FBXL16 and endometrial cancer: The abnormal expression of FBXL16 facilitated the MPA resistance of endometrial cancer by stabling the cyclin D1 protein; however, the proteasome-dependent degradation of cyclin D1 recognized by ubiquitinated E3 ligase was not the only one mechanism of MPA resistance.